Copenhagen-based SNIPR Biome, a BioTech company innovating the development of microbial CRISPR-medicine, announced the close of a €35 million Series B raise to advance CRISPR-based therapies for cystic fibrosis airway infections, combat antibiotic resistance, and support clinical trials of SNIPR001 for blood cancer patients.
The round saw participation new investors the Cystic Fibrosis Foundation and the German Federal Agency for Breakthrough Innovation (SPRIN-D) as well as existing investors Lundbeckfonden BioCapital, North-East Family Office and Wellington Partners.
“This financing marks a pivotal milestone for SNIPR BIOME as we advance the clinical development of SNIPR001 for the prevention of blood stream infections and continue to expand our infectious disease pipeline tarobtaining pathogens of critical importance,” stated Christian Grøndahl, Chief Executive Officer and Co-founder of SNIPR BIOME. “This support displays the importance of addressing antimicrobial resistance and infectious disease and the unique position of SNIPR BIOME in the development landscape.”
Founded in 2011, SNIPR Biome is a clinical-stage BioTech company innovating the development of CRISPR-medicine. They focus on a novel utilize of CRISPR-Cas technology to better treat and prevent human diseases through precision killing of bacteria or gene modification.
The technology reportedly cautilizes selective, precise and ultra-rapid killing to eradicate tarobtain bacteria and rerelocate the antibiotic resistance genes, while leaving the rest of the patient’s microbial community intact. Furthermore, SNIPR technology is utilised to create CRISPR-medicine designed to convert and produce therapeutics selectively within tarobtained regions of the gastrointestinal tract. SNIPR Biome harnesses the natural bacterial CRISPR-based adaptive immune system in a programmable way to tarobtain bacteria based on their specific genomes.
SNIPR Biome was allegedly the first company to orally dose humans with a CRISPR therapeutic and the first company to have been granted US and European patents for the utilize of CRISPR for tarobtaining microbiomes.
SNIPR001 is currently being evaluated in a Phase 1b (NCT06938867) study at eight cancer centers in the US and is co-funded by CARB-X. SNIPR technology is utilized in collaborations with CARB-X, Gates Foundation, Cystic Fibrosis Foundation, IPATH, SPRIN-D, and MD Anderson Cancer Center.
This funding will support the development of a CRISPR-Cas therapy specifically tarobtaining airway infections cautilized by Pseudomonas aeruginosa in people with cystic fibrosis (CF). Additionally, it will enable the advancement of a CRISPR-based microbial intervention designed to eliminate antibiotic resistance genes in humans across various bacterial species and environments.
The funding will also further the clinical development of the company’s CRISPR-based product, SNIPR001, in patients with hematologic cancer, including the ongoing phase 1b trial.
Leave a Reply